| Stereochemistry | ABSOLUTE |
| Molecular Formula | C41H63NO15.C2H4O2 |
| Molecular Weight | 869.9886 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 20 / 20 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(O)=O.CC[C@@H](C)C(=O)O[C@H]1[C@H](O)[C@H]2[C@@H](CN3C[C@@H](C)CC[C@H]3[C@@]2(C)O)[C@@H]4C[C@@]56O[C@@]7(O)[C@@H]([C@@H](OC(C)=O)[C@@H](OC(C)=O)[C@H]5[C@]14O)[C@]6(C)CC[C@@H]7OC(=O)[C@](C)(O)[C@@H](C)O
InChI
InChIKey=ONLYWKYYAQXZKP-OKVAQDKSSA-N
InChI=1S/C41H63NO15.C2H4O2/c1-10-19(3)34(47)56-33-28(46)27-23(17-42-16-18(2)11-12-25(42)38(27,9)50)24-15-39-32(40(24,33)51)30(54-22(6)45)29(53-21(5)44)31-36(39,7)14-13-26(41(31,52)57-39)55-35(48)37(8,49)20(4)43;1-2(3)4/h18-20,23-33,43,46,49-52H,10-17H2,1-9H3;1H3,(H,3,4)/t18-,19+,20+,23-,24-,25-,26-,27+,28+,29-,30+,31-,32+,33-,36-,37+,38+,39+,40-,41-;/m0./s1
| Molecular Formula | C2H4O2 |
| Molecular Weight | 60.052 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C41H63NO15 |
| Molecular Weight | 809.9366 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 20 / 20 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Protoveratrine B is one of two alkaloids isolated from the plant Veratrum albumen. The main effect of both alkaloids is vasodilation in all vascular beds thereby reducing blood pressure. In the 1950's it was recognized that Protoveratrine B is the preferred compound which can be administered at significantly higher doses before the patient begins to vomit.
Originator
Approval Year
Doses
AEs
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
Sourcing
Sample Use Guides
Protoveratrine B was administered to hypertensive patients as an oral tablet. Doses began at 0.3 to 0.5 mg single daily dose and raised incrementally until a marked fall in blood pressure was observed or the development on vomiting prohibited further increase.
Route of Administration:
Oral
Brain cortex slices of adult guinea pig were incubated for 30 min with 0.1 mM L-dopa. Brain slices were then pretreated with 5 uM protoveratrine (10 uM to 10 mM) for 20 min at 27 deg-C. Slices then incubated with glucose and L-dopa at 37 deg-C. The inclusion of Protoveratrine caused a decrease in the accumulation of L-dopa compared to control.
